Keeklee aims to reduce the time- and capital commitment to quality drug development, especially around IND. An estimated few thousand discovery programs that are at this stage, face multiple challenges primarily funding and uncertainty of licensing to top up the challenges of possible attrition, preventing the next generation discoveries to progress and the much needed drugs to reach the patients. Keeklee team has extensive experience of financing programs at this stage as well as drug development with several molecules developed that are in the clinic and on the market. The uniqueness of the model is design and execution of the project by global experts with very little capital requirement all the way to approval by a global agency, which is liked by investors, licensing partners and drug discovery teams alike. Using this model, we have delivered 15 INDs in the past 5 years for clients world-wide that have successfully obtained FIH approvals from EMA, USFDA, Health Canada, Medicines Australia. We have helped clients close seed and Series A funding for progressing portfolio from investors as well as soft funding agencies. Currently Keeklee has madate for the following programs- 1. Phase II program for Atopic Dermatitis / Psoriasis (small molecule) 2. Late Pre-clinical program for Ulcerative Colitis / systemic inflammation (small molecule) 3. Becacizumab (scaleup) 4. Erythropoetin Alpha (scaleup) 5. Infiximab (scaleup) 6. GOS (production, available for licensing) 7. rHSA (production, available for licensing / co-development for human use) Key Profiles include – • Akash Mathur, PhD, MBA • Dr.R.S.Rao, DVM/B.V.Sc & A.H., M.V.Sc.,Ph.D(UK), EU/UK Registered Toxicologist., Fellow International Academy of Toxicologic Pathology